.webp)
Diabetes treatment in Europe has changed a lot over the past decade. One of the major changes is the rising use of SGLT2 inhibitors. These modern medicines help the body remove extra sugar through urine. Along with controlling blood sugar, these inhibitors also support heart health and overall well-being.
More healthcare providers across Europe are choosing SGLT2 inhibitors as they suit modern healthcare needs. In this blog, we explain to you what SGLT2 inhibitors are and how they work. We also cover the top SGLT2 inhibitors in the Europe SGLT2 inhibitors market.
Understanding SGLT2 Inhibitors
The SGLT2 inhibitors market includes medicines that help lower blood sugar in a natural way. The kidneys usually filter sugar from the blood and return it to the body. The medicines stop the kidneys from getting the sugar back. As such, the extra sugar leaves the body through urine.
This method doesn’t depend on insulin. As such, it works well for people with severe diabetes. It’s also suitable for individuals who experience large changes in blood sugar. The easy-to-understand nature of these inhibitors and their ability to work reliably mean they are widely used across Europe.
Indication of SGLT2 Inhibitors
Cardiovascular
SGLT2 inhibitors were first used for diabetes. But, over time, their use also became common for heart health. Today, many doctors across Europe give these medicines to people with heart failure. These drugs help remove extra fluid from the body. They also reduce stress on the heart. Studies in Europe show fewer hospital visits for people with chronic heart failure. Because of these results, SGLT2 inhibitors have become an important part of heart treatment.
Chronic Kidney Disease (CKD)
Chronic kidney disease is a serious health issue. SGLT2 inhibitors are now widely used to slow it down. These medicines help protect the kidneys by reducing pressure inside the filtering system of the kidney. In Europe, doctors often prescribe them to people with CKD. These drugs help delay further kidney damage. They also lower the risk of kidney failure. This kidney protection makes SGLT2 inhibitors a key option in long-term kidney care.
Type 2 Diabetes
Type 2 diabetes is still the main reason for the prescription of SGLT2 inhibitors and other medications from the diabetes drug market. The ability of these inhibitors to lower blood sugar in a natural way makes them popular in Europe. They help the body remove extra sugar through urine. People also like that these medicines may support weight loss and reduce blood pressure.
Others
SGLT2 inhibitors are also being explored for other health benefits. Some doctors use them to help with weight management. This is especially the case with people having obesity linked to metabolic problems. Research is also looking at how these medicines may reduce inflammation and improve metabolic health. These uses are still developing. But they are showing how SGLT2 inhibitors could support overall health.
Europe SGLT2 Inhibitors Market Metrics
The Europe SGLT2 inhibitors market is expected to witness sustained growth. The market for these inhibitors stood at USD 4,524.49 million in 2024. It is projected to account for a CAGR of 6.7% during the forecast period, 2024 to 2032.
There has been a significant rise in the global population. This has led to an increased incidence of diabetes and related health conditions. As such, there is a greater need for SGLT2 inhibitors. Rising new drug approvals are having a favorable impact on the SGLT2 inhibitors market expansion.
Leading SGLT2 Inhibitors in Europe
Several SGLT2 inhibitors are commonly used across Europe. This is because SGLT2 inhibitors are safe and effective. They are helpful for diabetes and heart health.
Dapagliflozin
Dapagliflozin is a commonly used SGLT2 inhibitor in Europe. Doctors prescribe it for type 2 diabetes and heart failure. It’s also used for chronic kidney disease. It has been studied in European patients. The inhibitor has shown strong benefits for the heart and kidneys. As it’s approved for many conditions, specialists and regular doctors use it often.
Empagliflozin
Empagliflozin is another major option in the Europe SGLT2 inhibitors market. There’s strong research behind it. The inhibitor is known for reducing the risk of heart problems. It’s often given to patients who already have heart disease. The inhibitor is taken once a day, which makes it simple for patients to follow the treatment.
Canagliflozin
Canagliflozin is used to lower blood sugar and protect the kidneys. Its use varies from country to country in Europe. However, it remains an important choice for people who want strong blood sugar control. Over time, medical guidelines have highlighted the role of canagliflozin in supporting heart health.
Ertugliflozin
Ertugliflozin is available in several parts of Europe. Its use isn’t as widespread as others. However, it provides dependable blood sugar control. It’s often chosen when doctors need to combine it with other diabetes medicines.
Sotagliflozin
Sotagliflozin is a newer option. It’s a bit different from other SGLT2 inhibitors. This is because it works on two pathways instead of one. The inhibitor helps lower blood sugar. It may also support people with heart failure. Its use is slowly increasing as awareness about its benefits grows.
What’s New in SGLT Inhibitors Market?
August 2025: AstraZeneca announced findings from the BaxHTN Phase III study. The study showed that baxdrostat led to a statistically significant and clinically important drop in systolic blood pressure among patients with resistant hypertension.
February 2025: Researchers from Mount Sinai published results in The Lancet Diabetes & Endocrinology showing that sotagliflozin was associated with a 23% reduction in cardiovascular events.
Conclusion
SGLT2 inhibitors have changed how diabetes and chronic conditions are managed across Europe. Their straightforward working mechanism and several health benefits have made them a highly valuable treatment option. By protecting the heart and overall well-being, these inhibitors help patients live longer and healthier. As Europe places more emphasis on long-term health, the Europe SGLT2 inhibitors market is set to witness significant growth in the years to come.
